Clinical Trials Logo

Filter by:
NCT ID: NCT03585413 Not yet recruiting - Obesity Clinical Trials

Impact of a Specific Micronutrient-probiotic-supplement on Fatty Liver of Patients After Mini-Gastric Bypass Surgery

Start date: August 2018
Phase: Phase 3
Study type: Interventional

Aim of this prospective randomized intervention study is to evaluate the effect of a dietary intervention with a specific micronutrient-probiotic-combination for 12 weeks on fatty liver and cardiometabolic status in obese, nonalcoholic fatty liver disease (NAFLD) patients after Mini-Gastric Bypass (MGB) surgery.

NCT ID: NCT03584971 Not yet recruiting - Clinical trials for Behavioral Correlates of Estradiol

Estrogen and Cooperation, Competitiveness, and Risk Preferences

Start date: July 1, 2018
Study type: Observational

This study observes the effects of female cycle hormones on cooperation, competitiveness and risk preferences under experimental conditions. Especially, the causal effect of estradiol is isolated.

NCT ID: NCT03584750 Recruiting - Clinical trials for Chronic Pain Syndrome

Floating for Chronic Pain

Start date: June 12, 2018
Phase: N/A
Study type: Interventional

In recent years there has been a novel approach for the treatment of chronic pain: Floatation REST (restricted environmental stimulation therapy). Floating is a therapeutic approach, in which patients float in a specialized pool or tank on water that contains high concentrations of Epsom salt (Magnesium sulfate). Water is kept at skin temperature (35-36°C) and the pool or tank is shielded to provide almost complete darkness and silence. This therapeutic approach has proven to be effective in alleviating chronic pain. Due to the difficulties associated with designing a credible placebo control there have been no randomized controlled trials (RCTs) with patients blinding so far. Such blinding, however, is crucial, to assess the true therapeutic effect of the intervention. The investigators will conduct the first patient blinded RCT of Floatation REST for chronic pain with a credible placebo control for floating and a no-treatment group.

NCT ID: NCT03584321 Active, not recruiting - Clinical trials for Non-Obstructive Coronary Artery Disease

Retrospective Study to Estimate the Current Status of Patients With Non-Obstructive coroNary Artery Disease

Start date: September 13, 2017
Study type: Observational

The study will estimate the current status of participants with non-obstructive coronary artery disease confirmed via coronary angiography.

NCT ID: NCT03584204 Recruiting - Liver Cirrhosis Clinical Trials

Skeletal Muscle Parameters in Computed Tomography and Outcome in Liver Cirrhosis

Start date: January 1, 2018
Study type: Observational

The principal aim of this study is to analyse L3-SMI (skeletal muscle index) in a cohort of patients with decompensated liver cirrhosis and TIPS (transjugular intrahepatic portosystemic shunt), and compare the prognostic power with TPMT (transverse psoas muscle thickness). Furthermore, the role of myosteatosis, determined in CT by L3-SMI and MRI will be studied.

NCT ID: NCT03584165 Enrolling by invitation - Choroideremia Clinical Trials

Long-term Safety and Efficacy Follow-up of AAV2-REP1 for the Treatment of Choroideremia (SOLSTICE)

Start date: June 4, 2018
Study type: Observational

This is a long-term follow up evaluating the safety and efficacy of AAV2-REP1 used in antecedent choroideremia studies.

NCT ID: NCT03584009 Recruiting - Clinical trials for Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Start date: July 27, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase II, multicenter, open-label, randomized study to compare the efficacy of venetoclax in combination with fulvestrant compared with fulvestrant alone in women with ER+, HER2-negative, inoperable, locally advanced or MBC who experienced disease recurrence or progression during or after treatment with CDK4/6i therapy for at least 8 weeks.

NCT ID: NCT03583385 Not yet recruiting - Healthy Clinical Trials

Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study

Start date: July 24, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess bioequivalence between metformin hydrochloride (Glucophage® XR) manufactured in PT Merck Tbk, Indonesia (test drug) and metformin hydrochloride (Glucophage® XR) manufactured in Merck Santé, France (comparator drug) following single oral dose administration under fasting condition.

NCT ID: NCT03583346 Not yet recruiting - Clinical trials for Osteoarthritis, Knee

Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)

Start date: August 10, 2018
Phase: Phase 1
Study type: Interventional

The study will be conducted in participants with symptomatic knee OA to explore the safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of MAD of M6495.

NCT ID: NCT03582020 Active, not recruiting - Clinical trials for Nutritional Evaluation

Nutritional Evaluation - NuEva Study

Start date: June 4, 2018
Phase: N/A
Study type: Interventional

The NuEva study focusses on the development and the validation of nutritional concepts for healthy persons with different dietary habits, such as Western diet, flexitarians, vegetarians, as well as vegans. The practical nutritional concepts will ensure an optimal intake of macro- and micronutrients according to the guidelines of the nutritional societies and contribute to prevention and therapy of civilization disease, such as cardiovascular diseases. In addition, the contribution of the nutritional habits on health and disease status (focus cardiovascular diseases) will be evaluated.